Key features and details
- Rabbit polyclonal to ADAM33
- Suitable for: WB, IHC-P
- Reacts with: Mouse
- Isotype: IgG
Product nameAnti-ADAM33 antibody
DescriptionRabbit polyclonal to ADAM33
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Mouse
Predicted to work with: Rat
Synthetic peptide corresponding to Mouse ADAM33 aa 700 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in NIH3T3 whole cell lysate as well as the following Mouse tissue lysates: Placenta; Lung; Spleen; Heart. This antibody gave a positive result in IHC in the following FFPE tissue: mouse normal placenta.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab113740 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 108 kDa (predicted molecular weight: 87 kDa).|
|IHC-P||Use a concentration of 5 µg/ml.|
Tissue specificityExpressed in all tissues, except liver, with high expression in placenta, lung, spleen and veins.
Involvement in diseaseGenetic variations in ADAM33 are associated with susceptibility to asthma (ASTHMA) [MIM:600807]. The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with weezing due to spasmodic contraction of the bronchi.
Sequence similaritiesContains 1 disintegrin domain.
Contains 1 EGF-like domain.
Contains 1 peptidase M12B domain.
DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
modificationsThe precursor is cleaved by a furin endopeptidase.
- Information by UniProt
- A disintegrin and metalloprotease 33 antibody
- A disintegrin and metalloproteinase domain 33 antibody
- ADA33_HUMAN antibody
All lanes : Anti-ADAM33 antibody (ab113740) at 1 µg/ml
Lane 1 : Mouse Placenta Tissue Lysate
Lane 2 :
Mouse lung normal tissue lysate - total protein (ab29297)
Lane 3 : Spleen (Mouse) Tissue Lysate
Lane 4 : Heart (Mouse) Tissue Lysate
Lane 5 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 87 kDa
Observed band size: 108 kDa why is the actual band size different from the predicted?
Additional bands at: 28 kDa, 42 kDa, 68 kDa (possible cleavage fragment), 80 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 8 minutes
ADAM33 contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. The band observed at 68 kDa could potentially be a cleaved form of ADAM33 due to the presence of both a signal and pro peptide. The expression profile observed is consistent with what has been described in the literature (PMID: PMC2660367).
IHC image of ADAM33 staining in mouse normal placenta formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol B. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab113740, 5µg/ml, for 15 mins at room temperature. A Goat anti-Rabbit biotinylated secondary antibody was used to detect the primary, and visualized using an HRP conjugated ABC system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
ab113740 has not yet been referenced specifically in any publications.